Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Unknown 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 4Gynecologic 3Genitourinary 3Head & Neck 2Gastrointestinal 2Thoracic 1

Conditions

Urinary Bladder Neoplasms 2Muscle Invasive Bladder Cancer 1Carcinoma, Transitional Cell 1

Interventions

Docetaxel 409pembrolizumab 332Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
RC48 antibody × Genitourinary × Clear all
NCT07608224 2026-05-27

HOPE-07-MIBC

West China Hospital

Phase 2/3 Not yet recruiting
240 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT05911295 2026-04-20

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Seagen Inc.

Phase 3 Active not recruiting
412 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05979740 2023-08-31

RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

RenJi Hospital

Phase 2 Unknown
6 enrolled
Genitourinary

Muscle Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡